Future microbiologyPub Date : 2024-02-01Epub Date: 2023-12-21DOI: 10.2217/fmb-2023-0080
Kanchan Tiwari, Priya Patel, Aftab H Mondal, Kasturi Mukhopadhyay
{"title":"Interaction with lipopolysaccharide is key to efficacy of tryptophan- and arginine-rich α-melanocyte-stimulating hormone analogs against Gram-negative bacteria.","authors":"Kanchan Tiwari, Priya Patel, Aftab H Mondal, Kasturi Mukhopadhyay","doi":"10.2217/fmb-2023-0080","DOIUrl":"10.2217/fmb-2023-0080","url":null,"abstract":"<p><p><b>Aim:</b> In order to search for novel antibacterial therapeutics against Gram-negative bacteria, the antibacterial efficacies and mechanism of action of tryptophan- and arginine-rich α-melanocyte-stimulating hormone analogs were investigated. <b>Materials & methods:</b> We performed a killing assay to determine their efficacy; fluorescence, microscopic studies were used to understand their mechanism and peptide-lipopolysaccharide interaction. A checkerboard assay was used to find the effective combination of peptide and antibiotics. <b>Results:</b> Ana-peptides displayed good killing activity against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>. Their strong interaction with lipopolysaccharide damaged the bacterial membranes and led to their subsequent death. Ana-5, the highest cationic and hydrophobic analog, emerged as the most potent peptide, showing synergistic action with rifampicin and erythromycin. <b>Conclusion:</b> Ana-5 can be presented as an important therapeutic candidate against bacterial infections.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"195-211"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-02-01Epub Date: 2023-11-29DOI: 10.2217/fmb-2023-0191
Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Mariana Castanheira
{"title":"Use of isavuconazole antifungal medicine to treat mold infections in Asia and the Western Pacific region: a plain language summary.","authors":"Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Mariana Castanheira","doi":"10.2217/fmb-2023-0191","DOIUrl":"10.2217/fmb-2023-0191","url":null,"abstract":"<p><strong>What is this summary about?: </strong>Molds are types of fungus that can invade humans. It can cause a disease called invasive mold infection (IMI) and make people sick or cause death. This is a summary of a study that looked at mold samples collected from people in Asia and the Western Pacific region to check if an antifungal medicine called isavuconazole (ISC) can stop the growth of or kill these molds.</p><p><strong>What were the results?: </strong>One type of mold known as <i>Aspergillus</i> or type 1 molds, was more common than other molds. Antifungal medicines including ISC, posaconazole, voriconazole, and itraconazole slowed or stopped the growth of the type 1 molds. ISC was very active in slowing or stopping the growth of this mold. Other molds, known as non-<i>Aspergillus</i> or type 2 mold, were less common. The antifungals medicines mentioned above were able to slow or stop the growth of some but not all of the type 2 molds.</p><p><strong>What do the results of the study mean?: </strong>ISC stopped the growth of most type 1 molds and was as good as the other antifungal medicines against type 2 molds.</p><p><strong>What is the purpose of this plain language summary?: </strong>The purpose of this plain language summary is to help you to understand the findings from recent research. The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence not on the results of a single study.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"173-180"},"PeriodicalIF":2.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-02-01Epub Date: 2024-02-02DOI: 10.2217/fmb-2023-0175
Modawy Em Elkhalifa, Muhammad Ashraf, Alshebli Ahmed, Assad Usman, Alashary Ae Hamdoon, Mohammed A Elawad, Meshari G Almalki, Osama F Mosa, Laziz N Niyazov, Muhammad Ayaz
{"title":"Polyphenols and their nanoformulations as potential antibiofilm agents against multidrug-resistant pathogens.","authors":"Modawy Em Elkhalifa, Muhammad Ashraf, Alshebli Ahmed, Assad Usman, Alashary Ae Hamdoon, Mohammed A Elawad, Meshari G Almalki, Osama F Mosa, Laziz N Niyazov, Muhammad Ayaz","doi":"10.2217/fmb-2023-0175","DOIUrl":"10.2217/fmb-2023-0175","url":null,"abstract":"<p><p>The emergence of multidrug-resistant (MDR) pathogens is a major problem in the therapeutic management of infectious diseases. Among the bacterial resistance mechanisms is the development of an enveloped protein and polysaccharide-hydrated matrix called a biofilm. Polyphenolics have demonstrated beneficial antibacterial effects. Phenolic compounds mediate their antibiofilm effects via disruption of the bacterial membrane, deprivation of substrate, protein binding, binding to adhesion complex, viral fusion blockage and interactions with eukaryotic DNA. However, these compounds have limitations of chemical instability, low bioavailability, poor water solubility and short half-lives. Nanoformulations offer a promising solution to overcome these challenges by enhancing their antibacterial potential. This review summarizes the antibiofilm role of polyphenolics, their underlying mechanisms and their potential role as resistance-modifying agents.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"255-279"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extracellular vesicles from <i>Lacticaseibacillus paracasei</i> PC-H1 inhibit HIF-1α-mediated glycolysis of colon cancer.","authors":"Yangqian Shi, Chunliang Zhang, Wanyu Cao, Luyi Li, Kaili Liu, Hanyue Zhu, Fikadu Balcha, Yong Fang","doi":"10.2217/fmb-2023-0144","DOIUrl":"10.2217/fmb-2023-0144","url":null,"abstract":"<p><p><b>Aims:</b> Extracellular vesicles from <i>Lacticaseibacillus paracasei</i> PC-H1 have antiproliferative activity of colon cells, but the effect on glycolytic metabolism of cancer cell remains enigmatic. The authors investigated how <i>Lacticaseibacillus paracasei</i> extracellular vesicles (LpEVs) inhibit the growth of colon cancer cells by affecting tumor metabolism. <b>Materials & methods:</b> HCT116 cells were treated with LpEVs and then differentially expressed genes were analyzed by transcriptome sequencing, the sequencing results were confirmed <i>in vivo</i> and <i>in vitro</i>. <b>Results:</b> LpEVs entered colon cancer cells and inhibited their growth. Transcriptome sequencing revealed differentially expressed genes were related to glycolysis. Lactate production, glucose uptake and lactate dehydrogenase activity were significantly reduced after treatment. LpEVs also reduced HIF-1α, GLUT1 and LDHA expression. <b>Conclusion:</b> LpEVs exert their antiproliferative activity of colon cancer cells by decreasing HIF-1α-mediated glycolysis.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"227-239"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-02-01Epub Date: 2024-01-31DOI: 10.2217/fmb-2023-0127
Sara Bernardi, Davide Gerardi, Sibylle Bartsch, Guido Macchiarelli, Elmar Hellwig, Ali Al-Ahmad
{"title":"Antimicrobial therapy using VIS plus water-filtered infrared-A as an alternative method to treat oral diseases.","authors":"Sara Bernardi, Davide Gerardi, Sibylle Bartsch, Guido Macchiarelli, Elmar Hellwig, Ali Al-Ahmad","doi":"10.2217/fmb-2023-0127","DOIUrl":"10.2217/fmb-2023-0127","url":null,"abstract":"<p><p>Oral biofilm is the main cause of pathologies affecting the hard and soft oral tissues around teeth. Its main components are the periodontal pathogens and other bacteria of the supragingival and subgingival biofilm. Different alternative strategies that could be adjuvants to the usual periodontal treatments used to eliminate biofilms are available. One of these methods is antimicrobial photodynamic therapy using VIS and water-filtered infrared-A combined with a photosensitizer. In this review, different recent studies were collected to evaluate the antimicrobial effects of antimicrobial photodynamic therapy and the effectiveness of different types of photosensitizers.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"241-254"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-02-01Epub Date: 2023-11-07DOI: 10.2217/fmb-2023-0051
Quezia Damaris Jones Severino Vasconcelos, Marisa Jadna Silva Frederico, Renata de Sousa Alves, Tereza de Jesus Pinheiro Gomes Bandeira, Maria Elisabete Amaral de Moraes, Gislei Frota Aragão
{"title":"Effects of whey protein supplementation on gut microbiota of Wistar rats with valproic acid-induced autism symptoms.","authors":"Quezia Damaris Jones Severino Vasconcelos, Marisa Jadna Silva Frederico, Renata de Sousa Alves, Tereza de Jesus Pinheiro Gomes Bandeira, Maria Elisabete Amaral de Moraes, Gislei Frota Aragão","doi":"10.2217/fmb-2023-0051","DOIUrl":"10.2217/fmb-2023-0051","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the effects of whey protein (WP) supplementation (1.24 mg/g, 24 days) in rats with autism spectrum disorder (ASD) induced by valproic acid (400 mg/kg, single dose). <b>Materials & methods:</b> Wistar rats (14 days old) were divided into four groups: control, ASD, ASD plus WP and WP. <b>Results:</b> WP increased bacterial diversity and the number of colonies. Bacteria from the Firmicutes phylum were predominantly found in the supplemented groups (p < 0.05). WP also improved the animals' memory in the Y-maze test and decreased the time that male animals spent in the 'solitary chamber' (p < 0.05). <b>Conclusion:</b> WP supplementation positively influenced gut microbiota, along with memory.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"213-226"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-02-01Epub Date: 2024-02-08DOI: 10.2217/fmb-2023-0070
Gleyce Ha de Souza, Marcia Sm Vaz, Joyce A Dos Santos Radai, Thiago L Fraga, Luana Rossato, Simone Simionatto
{"title":"Synergistic interaction of polymyxin B with carvacrol: antimicrobial strategy against polymyxin-resistant <i>Klebsiella pneumoniae</i>.","authors":"Gleyce Ha de Souza, Marcia Sm Vaz, Joyce A Dos Santos Radai, Thiago L Fraga, Luana Rossato, Simone Simionatto","doi":"10.2217/fmb-2023-0070","DOIUrl":"10.2217/fmb-2023-0070","url":null,"abstract":"<p><p><b>Objective:</b> The antimicrobial activities of the synergistic combination of carvacrol and polymyxin B against polymyxin-resistant <i>Klebsiella pneumoniae</i> were evaluated. <b>Methods:</b> The methods employed checkerboard assays to investigate synergism, biofilm inhibition assessment and membrane integrity assay. In addition, the study included <i>in vivo</i> evaluation using a mouse infection model. <b>Results:</b> The checkerboard method evaluated 48 combinations, with 23 indicating synergistic action. Among these, carvacrol 10 mg/kg plus polymyxin B 2 mg/kg exhibited <i>in vivo</i> antimicrobial activity in a mouse model of infection, resulting in increased survival and a significant decrease in bacterial load in the blood. <b>Conclusion:</b> Polymyxin in synergy with carvacrol represents a promising alternative to be explored in the development of new antimicrobials.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"181-193"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139702297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-03-01DOI: 10.2217/fmb-2023-0248
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
{"title":"Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting <i>Acinetobacter baumannii</i>.","authors":"Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye","doi":"10.2217/fmb-2023-0248","DOIUrl":"10.2217/fmb-2023-0248","url":null,"abstract":"<p><p>Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of <i>Acinetobacter baumannii-calcoaceticus</i> complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against <i>Acinetobacter</i> but is prone to hydrolysis by β-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane β-lactamase inhibitor with activity against Ambler classes A, C and D serine β-lactamases that restores sulbactam activity both <i>in vitro</i> and <i>in vivo</i> against multidrug-resistant ABC. Sulbactam-durlobactam is a promising alternative therapy for the treatment of serious <i>Acinetobacter</i> infections, which can have high rates of mortality.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"563-576"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Establishment and evaluation of MIRA-qPCR assay for the rapid and sensitively detection of <i>Mycoplasma pneumoniae</i>.","authors":"Qiao Qiao, Yi-Yue Ge, Xiao-Juan Zhu, Kang-Chen Zhao, Yin Chen, Lun-Biao Cui, Tao Wu","doi":"10.1080/17460913.2024.2398886","DOIUrl":"10.1080/17460913.2024.2398886","url":null,"abstract":"<p><p><b>Aim:</b> <i>Mycoplasma pneumoniae</i> (MP) is a common cause of respiratory infections, and its incidence has increased post-COVID-19 due to \"immune debt.\" Real-time quantitative polymerase chain reaction (qPCR) is the standard for detecting MP, but it has a lengthy detection time. This study aimed to establish a highly sensitive rapid detection method for MP.<b>Materials & methods:</b> We developed an integrated assay combining multienzyme isothermal rapid amplification (MIRA) with qPCR, referred to as MIRA-qPCR, for the rapid detection of MP, delivering results within approximately 40 min.<b>Results:</b> The analytic sensitivity of the MIRA-qPCR assay was 10 copies per reaction, and it exhibited no cross-reactivity with other respiratory pathogens, ensuring high specificity. Clinical sample analysis demonstrated higher sensitivity for MIRA-qPCR compared to qPCR reported in the literature, and 100% concordance with commercial qPCR kit.<b>Conclusion:</b> The MIRA-qPCR method established in this study is a promising tool for the clinical detection of MP, offering significant advantages for the rapid diagnosis of MP infections.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1455-1461"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-01-31DOI: 10.2217/fmb-2023-0160
Francisca B Stefany Aires do Nascimento, Lívia Gurgel do Amaral Valente Sá, João B de Andrade Neto, Lisandra Juvêncio da Silva, Daniel Sampaio Rodrigues, Vitória P de Farias Cabral, Amanda Dias Barbosa, Lara E Almeida Moreira, Camille R Braga Vasconcelos, Bruno Coêlho Cavalcanti, Maria E França Rios, Jacilene Silva, Emmanuel Silva Marinho, Helcio Silva Dos Santos, Jacó Rl de Mesquita, Marina Duarte Pinto Lobo, Manoel Odorico de Moraes, Hélio V Nobre Júnior, Cecília Rocha da Silva
{"title":"Antimicrobial activity of hydralazine against methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus</i>.","authors":"Francisca B Stefany Aires do Nascimento, Lívia Gurgel do Amaral Valente Sá, João B de Andrade Neto, Lisandra Juvêncio da Silva, Daniel Sampaio Rodrigues, Vitória P de Farias Cabral, Amanda Dias Barbosa, Lara E Almeida Moreira, Camille R Braga Vasconcelos, Bruno Coêlho Cavalcanti, Maria E França Rios, Jacilene Silva, Emmanuel Silva Marinho, Helcio Silva Dos Santos, Jacó Rl de Mesquita, Marina Duarte Pinto Lobo, Manoel Odorico de Moraes, Hélio V Nobre Júnior, Cecília Rocha da Silva","doi":"10.2217/fmb-2023-0160","DOIUrl":"10.2217/fmb-2023-0160","url":null,"abstract":"<p><p><b>Background:</b> <i>Staphylococcus aureus</i> is a human pathogen responsible for high mortality rates. The development of new antimicrobials is urgent. <b>Materials & methods:</b> The authors evaluated the activity of hydralazine along with its synergism with other drugs and action on biofilms. With regard to action mechanisms, the authors evaluated cell viability, DNA damage and molecular docking. <b>Results:</b> MIC and minimum bactericidal concentration values ranged from 128 to 2048 μg/ml. There was synergism with oxacillin (50%) and vancomycin (25%). Hydralazine reduced the viability of biofilms by 50%. After exposure to hydralazine 2× MIC, 58.78% of the cells were unviable, 62.07% were TUNEL positive and 27.03% presented damage in the comet assay (p < 0.05). Hydralazine showed affinity for DNA gyrase and TyrRS. <b>Conclusion:</b> Hydralazine is a potential antibacterial.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"91-106"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}